Invention Grant
US08840888B2 Dosage regimen for administering a CD19XCD3 bispecific antibody
有权
用于给予CD19XCD3双特异性抗体的剂量方案
- Patent Title: Dosage regimen for administering a CD19XCD3 bispecific antibody
- Patent Title (中): 用于给予CD19XCD3双特异性抗体的剂量方案
-
Application No.: US13504665Application Date: 2010-10-27
-
Publication No.: US08840888B2Publication Date: 2014-09-23
- Inventor: Dirk Nagorsen , Peter Kufer , Gerhard Zugmaier , Patrick Baeuerle
- Applicant: Dirk Nagorsen , Peter Kufer , Gerhard Zugmaier , Patrick Baeuerle
- Applicant Address: DE Munich
- Assignee: Micromet AG
- Current Assignee: Micromet AG
- Current Assignee Address: DE Munich
- Agency: Marshall, Gerstein & Borun LLP
- Priority: EP09174104 20091027
- International Application: PCT/EP2010/066207 WO 20101027
- International Announcement: WO2011/051307 WO 20110505
- Main IPC: A61K39/395
- IPC: A61K39/395 ; G01N33/50 ; C07K16/28 ; A61K39/00
Abstract:
Provided herein is a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19.times.CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient.
Public/Granted literature
- US20120328618A1 DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY Public/Granted day:2012-12-27
Information query
